GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

GLP-1 receptor agonists do not affect cardiovascular, kidney, or safety outcomes regardless of SGLT2 inhibitor use in patients with type 2 diabetes.

By Dr. Sushama R. Chaphalkar, PhD. Prescriptions of GLP-1RAs and SGLT2 inhibitors in type 1 diabetes patients rose from 2010 ...

About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in a ...

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is ...

Lexicon's Inpefa faces fierce competition from established SGLT2 inhibitors, like Farxiga and Jardiance. Read why LXRX stock ...

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with a lower risk for incidental Parkinson disease among older adults with type 2 diabetes.

BOSTON — The use of sodium-glucose cotransporter-2 (SGLT2) inhibitors is associated with reduced short- and long-term mortality among patients with pulmonary arterial hypertension (PAH ...

The risk for kidney function decline is lower among new users of sodium glucose cotransporter-2 inhibitors (SGLT2i) vs glucagon-like peptide 1 receptor agonists (GLP-1RA), a real-world study of ...

Renal glucose reabsorption involves two transporter families: the SGLTs secondary active Na + /D-glucose co-transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the ...

S.S. ANSWER: Empagliflozin (Jardiance) and dapagliflozin (Farxiga) are both medicines for diabetes in the SGLT2 inhibitor class. These work by causing the kidneys to release sugar from the blood ...